"TB-500 has been proven in human trials."
This page has not yet been reviewed by a credentialed medical professional. It is educational and is not medical advice.
Rating:
Human trials exist for full-length thymosin beta-4, which is a different molecule from TB-500.
The evidence
A randomized trial in 96 heart attack patients used recombinant full-length thymosin beta-4 and found a benefit in a subgroup but not overall. TB-500, the fragment sold online, has no comparable trial.
Sources
- Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. (Cardiovasc Res, 2025)
- Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. (Expert Opin Biol Ther, 2012)